Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies, Inc. to Present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference

Jul 26, 2010

St. Louis, MO., July 26, 2010 – ISTO Technologies, Inc. announced today that it will participate in the BMO Capital Markets’ 10th Annual Focus on Healthcare Conference to be held at the Sheraton New York Hotel & Towers in New York, NY on August 5,1 2010. Mitchell Seyedin, Ph. D., President and CEO, is scheduled to present a 30-minute overview of the company at 3:00 p.m. Eastern Time on Thursday, August 5th. The conference will feature presentations from over 90 public and private healthcare companies in the biotechnology, medical devices healthcare services and pharmaceutical areas.

ISTO’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged tissue. The company believes that the two clinical-stage products currently comprising ISTO’s cell-based program, DeNovo® ET and NuQu™, represent considerable improvements over other treatments currently available or in clinical development and address two significant unmet medical needs in orthopaedics (damaged knee cartilage and discogenic back pain). These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells. Additionally, ISTO’s patented cell-expansion process allows for a scalable, off-the-shelf solution not available in competing technologies focused on cartilage regeneration.

DeNovo ET, a scaffold-free engineered cartilage tissue, is intended for the repair of damaged articular cartilage in the knee. ISTO believes the product represents a novel treatment for cartilage repair and has the potential to repair damaged knee cartilage more effectively than other cartilage repair therapies currently available or in clinical development.

NuQu is an injectable juvenile chondrocyte therapy for early intervention and restoration of disc function in patients suffering from discogenic back pain. As with DeNovo ET, NuQu’s use of juvenile chondrocytes offers unique regenerative potential when compared to other developmental therapies. There is currently no approved treatment for invertebral disc repair and this minimally-invasive ambulatory treatment potentially represents a cost-effective solution for discogenic back pain.

In addition to ISTO’s cell-based cartilage programs, the company is currently producing and marketing, InQu®, a bone graft extender and substitute. InQu contains integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications.

About ISTO
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.

To top